Group | Author/year of publication | Disease | Study design | Number of individuals | Loss-to-follow-up (%) | Main results |
---|---|---|---|---|---|---|
Interventions with opioid agonist treatment | Achmad, Y.M. et al (2009) | HIV | Cohort | 223 | No difference between the intervention group and the control group. No data are available. | Virological response (HIV viral load): IG: 97 % versus CG: 90 %, p = 0.27 Immunological response (CD4 cell count): IG: 69 % versus CG: 57 %, p = 0.93. |
Batki, S.L. et al (2002) | TB | RCT | 111 | 52% | TBC completion (≥ 80 % of the doses administrated): 59.5 % in Standard Methadone Treatment, 77.1 % in Minimal Methadone Treatment and 13.1 % in Routine Care, p < 0.01. | |
Bruce, D.R. et al (2012) | HCV | RCT | 21 | 67% | SVR: Six of ten in the intervention group and one of four in the control group, achieved SVR | |
Lucas, G.M. et al (2010) | HIV | RCT | 93 | 17% | HIV RNA and CD4 cell count: No significant differences between opioid agonist therapy in the clinic-based buprenorphine strategy versus specialized opioid treatment program were found (p = 0.31 and p = 0.16, respectively) | |
Morozova, O. et al (2013) | TB | Cohort | 110 | 18 % | Treatment completion: IG: 90 % versus CG: 74 %, p = 0.03. | |
Tetrault, J.M. et al (2012) | HIV | RCT | 47 | 30% | Virological response (HIV viral load): Descreased from 58 % at baseline to 43 % at 12 weeks in IG, and from 56 % to 35 % in CG, p = 0.84 and p = 0.27, respectively. | |
Interventions without opioid agonist treatment | Groessl, E.J. et al (2017) | HCV | RCT | 79 | 37% | SVR: 67 % in IG versus 55 % in CG, p = 0.23. |
Ho, S.B. et al (2015) | HCV | RCT | 363 | 53% | SVR: 16 % and 8 % in IG and in CG, respectively, achieved SVR. OR 2.26 (95 % CI: 1.15-4.44, p = 0.02) SVR (active substance users and alcohol dependents): IG: 11 % versus CG: 7 %, p = 0.49. | |
Sánchez, G.C. et al (2012) | HIV | Cohort | 119 | In IG 13 % versus in CG 8 % permanently discontinued treatment. | Virological response (HIV RNA load < 50 copies/mL) at week 48: 93 % (95 % CI = 87 % - 99 %) in IG versus 94 % (95% CI = 84 % - 100 %) in CG. Virological response (HIV RNA load < 50 copies/mL) at week 96: 87 % (95 % CI = 79 % - 95 %) in IG, and 88 % (95% CI = 78 % - 97 %) in CG. No significant differences were found, Kaplan-Meier estimates, log rank test, p =0.965. | |
Simoni, J.M. et al (2007) | HIV | RCT | 136 | All recruited were followed up, but only 59 % at baseline, 65 % at three months, and 61 % at six months reported adherence on 95 % or more. | HIV RNA: HIV suppression was not found significantly different between the integrated group and the control group at baseline, three months and six months follow up. |